United Kingdom

People: Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

18 Jan 2019
Change (% chg)

$-0.01 (-0.48%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Ringrose, Peter 

Dr. Peter S. Ringrose, Ph.D., is Independent Director of Rigel Pharmaceuticals Inc., since February 2005. Dr. Ringrose's experience in the pharmaceutical industry spans more than 40 years and includes key leadership positions as Senior Vice President for Worldwide Drug Discovery and Medicinal R & D Europe at Pfizer Inc., a pharmaceutical company, and Division Director of Chemotherapy, Infectious Diseases and Molecular Sciences at the Sandoz Research Institute in Vienna, Austria. In 2002, Dr. Ringrose retired from Bristol-Myers Squibb, a pharmaceutical company, where he served as Chief Scientific Officer from January 2000 to December 2002, as well as President of the Pharmaceutical Research Institute from January 1997 to December 2002. Dr. Ringrose served as chair of the Biotechnology and Biological Sciences Research Council (UK) from 2003 until 2009, and was a member of the UK Government's Technology Strategy Board. He is a Council member of the Foundation for Science and Technology in the United Kingdom and also chairs the Corporate Partnership Board at Pembroke College, Cambridge where he is a lifetime Honorary Pitt Fellow. Dr. Ringrose served on the board of directors of Theravance, Inc Dr. Ringrose received a B.S., an M.A. and a Ph.D. from the University of Cambridge.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Raul Rodriguez


Dean Schorno


Dolly Vance


Anne-Marie Duliege


Eldon Mayer


Nelson Cabatuan

As Of  31 Dec 2017